Sopan Pharmaceuticals Limited (SOPL)
Manufacturing · Rs. 725.00 -9.00 (-1.23%) as of Sep 3, 2026
Price — last 6 months
Full chart →Open
728.00
High / Low
733.90 / 720.20
Prev. close
734.00
Volume
26,050
52-week high
—
52-week low
—
Market cap
—
Shares outstanding
—
MASTER score
Mechanical 0–100 technical ranking. Methodology →
Promoter holding—
Public holding—
Stock performance
1-week change
-4.35%
1-month change
-10.27%
3-month change
—
6-month change
—
YTD change
—
1-year change
—
1-month high
826.00
1-month low
705.00
From 52-week high
—
From 52-week low
—
180-day avg price
792.99
360-day avg price
792.99
Avg volume (1w)
19,351
Avg volume (1m)
25,853
Avg volume (6m)
49,803
Avg volume (12m)
49,803
Daily volatility (1m)
1.58%
Beta vs NEPSE (1y)
2.50
Valuation
EPS (annualized)
—
EPS (TTM)
—
P/E
—
P/B
—
Book value / share
—
ROE
—
ROA
—
Net profit margin
—
Graham number
—
Dividend yield
—
Dividend
—
P/E and P/B use the latest close over per-share values from the company's most recent filed statement. Full dividend history →
Key indicators vs Manufacturing
EPS (Rs.)
N/A
min -6.29avg 452.86max 1,712.27
—
P/E
N/A
min 21.38avg 33.31max 47.11
—
P/B
N/A
min 2.01avg 4.98max 9.01
—
Networth / Share (Rs.)
N/A
min 98.04avg 1,518.08max 5,537.13
—
ROE (%)
N/A
min 0.00avg 10.89max 30.92
—
Technical indicators
| RSI (14) | 39.50 | Neutral |
| MACD | -21.19 | Bearish |
| EMA 5 | 734.73 | Bearish |
| EMA 20 | 765.38 | Bearish |
| EMA 180 | — | — |
| SMA 50 | 812.92 | Bearish |
| SMA 200 | — | — |
Pivot levels (classic)
S3
705.13S2
712.67S1
718.83PP
726.37R1
732.53R2
740.07R3
746.23Key financials — last 8 quarters
worsebetter vs same quarter last yearamounts in Rs · per-share in RsNo filed statements found.
More Manufacturing stocks
SOPL — frequently asked questions
What is Sopan Pharmaceuticals Limited's share price?
Rs. 725.00 as of Sep 3, 2026, the latest NEPSE trading session (-1.23% on the day).
What dividend did SOPL pay?
No dividend on record for the most recent fiscal year in our data.
Prices from the latest NEPSE session; fundamentals from the company's published quarterly statements. Research reference only — not investment advice.